Lipid Regulators Global Market Report 2024

The lipid regulators market size has grown strongly in recent years. It will grow from $6.83 billion in 2023 to $7.29 billion in 2024 at a compound annual growth rate (CAGR) of 6.8%. The growth during the historic period can be attributed to the increased prevalence of lifestyle diseases, the growth in the aging population, increased awareness of lipid regulators, rising healthcare expenditure, and an increased focus on healthcare prevention.

The lipid regulators market size is expected to see strong growth in the next few years. It will grow to $9.55 billion in 2028 at a compound annual growth rate (CAGR) of 7%. The growth in the forecast period can be attributed to the increasing prevalence of cardiovascular diseases, the rising incidence of atherosclerosis with aging, increasing obesity rates, the growing prevalence of metabolic syndrome, and a growing focus on personalized medicine. Major trends expected during the forecast period include advancements in drug development, the integration of digital health solutions, adoption of value-based pricing models, increased demand for over-the-counter medications, and an emphasis on enhancing patient-centered medication approaches.

The increasing incidence of ischemic heart disease is anticipated to drive the expansion of the lipid regulator market in the foreseeable future. Ischemic heart disease (IHD), also known as coronary artery disease (CAD), involves the narrowing or blockage of coronary arteries, leading to reduced blood flow to the heart muscle. Factors contributing to the rising prevalence of ischemic heart disease include unhealthy diets, smoking, obesity, hypertension, and diabetes. Lipid regulators play a crucial role in managing ischemic heart disease by lowering LDL cholesterol, elevating HDL cholesterol, stabilizing arterial plaques, reducing inflammation, and enhancing endothelial function, thus mitigating the risk and severity of ischemic events. For instance, data from the Australian Institute of Health and Welfare (AIHW) in December 2023 revealed that between 2020 and 2021, there were 160,000 hospitalizations attributed to ischemic heart disease, resulting in 17,300 deaths in 2021 alone. Consequently, the growing prevalence of ischemic heart disease is a key driver behind the expansion of the lipid regulator market.

Leading companies in the lipid regulator market are actively developing advanced oral lipid-lowering medications to address high low-density lipoprotein (LDL) cholesterol levels in patients with heart conditions. These oral medications are targeted at individuals with inherited genetic abnormalities causing high cholesterol or those diagnosed with heart disease. For example, in May 2022, Sun Pharmaceutical Industries Limited, a specialty generic pharmaceutical company based in India, introduced Bempedoic Acid Brillo in India, an oral medication designed to provide innovative therapy for high LDL cholesterol levels in cardiac patients. Bempedoic acid exerts a dual mode of action by inhibiting ATP citrate lyase, an enzyme involved in cholesterol production, and activating AMP-activated protein kinase (AMPK), which regulates cholesterol synthesis in the liver. Its once-daily oral administration offers enhanced convenience for patients compared to certain other cholesterol-lowering medications.

In April 2023, Luye Pharma Group, a pharmaceutical company based in China, entered into a partnership with Duopharma Marketing Sdn Bhd with the objective of leveraging Duopharma Biotech's cardiovascular expertise and Luye Pharma's advanced technology to market and distribute a traditional Chinese medicine utilizing innovative fermentation techniques. This medicine harnesses unique red yeast rice to effectively manage cholesterol levels. Duopharma Marketing Sdn Bhd, a subsidiary of Duopharma Biotech Berhad (Duopharma Biotech), specializes in the manufacture of lipid regulators and cholesterol-lowering agents in Malaysia.

Major companies operating in the lipid regulators market are Pfizer Inc., AbbVie Inc., Bayer AG, Sanofi SA, AstraZeneca plc, Bristol-Myers Squibb Company, Abbott Laboratories, Novartis AG, Amgen Inc., Merck KGaA, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Hetero Drugs Limited, Dr. Reddy's Laboratories Ltd., Biocon Ltd., Alnylam Pharmaceuticals Inc., Amarin Corporation plc, Arrowhead Pharmaceuticals Inc., Kowa Pharmaceuticals America Inc., Esperion Therapeutics Inc., Bentley Pharmaceuticals Inc., Sun Pharmaceutical Industries Limited, Andrx Corporation.

North America was the largest region in the lipid regulators market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lipid regulators market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the lipid regulators market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Lipid regulators, also referred to as lipid-lowering drugs or hypolipidemic agents, are medications utilized to regulate blood lipid levels, specifically cholesterol and triglycerides. These drugs play a crucial role in minimizing the risk of cardiovascular disease, and they also possess anti-inflammatory properties that aid in stabilizing existing plaques and reducing the likelihood of plaque rupture and associated cardiovascular events.

The main types of lipid regulators include narcotic analgesics, angiotensin-converting enzyme (ACE) inhibitors, respiratory agents, diuretics, calcium antagonists, hormonal contraceptives, and others. Lipid regulators are medications designed to manage and control lipid levels in the body, including cholesterol and triglycerides. They are employed in treating various conditions such as hypercholesterolemia, hypertriglyceridemia, coronary artery disease, among others. These medications can be administered orally or via injection, and they find applications in pharmaceuticals, vaccines and drugs, scientific research, nutrition and supplements, food and beverages, and other sectors.

The lipid regulator market research report is one of a series of new reports that provides lipid regulator market statistics, including the lipid regulator industry global market size, regional shares, competitors with lipid regulator market share, detailed lipid regulator market segments, market trends, and opportunities, and any further data you may need to thrive in the lipid regulator industry. These lipid regulator market research reports deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The lipid regulators market consists of sales of ezetimibe, bile acid sequestrants, fibrates, and cholesterol absorption inhibitors. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.